The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


ERC Advanced Grant for Prof. Thomas Thum

For years, Professor Dr. Dr. Thomas Thum, head of the Institute for Molecular and Translational Therapy Strategies at the Hannover Medical School (MHH) and institute director of Fraunhofer ITEM, has been researching a remedy for the hitherto incurable cardiac fibrosis. He has already received the highest science funding from the European Union for this, an European Research Council (ERC) Advanced Grant.


Review published by TRAIN-HEART fellow Joana Silva on non-coding RNAs involved in cardiac hypertrophy

Review title: Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy.

Published in Cells 2022, 11(11), 1805;


How to repair a broken heart with pluripotent stem cell-derived cardiomyocytes?

The Eschenhagen group at the University Medical Center Hamburg-Eppendorf recently published an article about the progress in the field of heart regeneration.


Chitosan hydrogels incorporating colloids for sustained drug delivery

The research group at Lyon Unversity recently published a review to report on the many existing complex systems composed of chitosan hydrogels embedding different types of colloids used as drug delivery devices to delay the release of drugs. The various biomedical applications of such final systems are also detailed in this review.


Dr. Marc Hirt presented his work at the Frontiers in Cardiovascular Biomedicine congress 2022

Lead scientist Dr. Marc Hirt of University Medical Center Hamburg-Eppendorf and supervisor of Kinga Wrona (TRAIN-HEART fellow) presented his work at the Frontiers in Cardiovascular Biomedicine congress 2022